Peter Kleinhenz, co-founder, COO and CFO of Armatus Bio, Inc., is an accomplished life sciences executive and entrepreneurial strategist with extensive C-suite leadership, VC partnership and board membership experience. Prior to Armatus Bio, Mr. Kleinhenz co-founded Clarametyx Biosciences, Inc. and served as CFO and CBO at Myonexus Therapeutics until its acquisition by Sarepta in 2019. He was President and CEO of Woodhall Consulting, LLC, a strategic planning and venture development consultancy focused on life sciences. Mr. Kleinhenz was also previously a General Partner/Managing Director at Fletcher Spaght Ventures and CID Capital, Inc., leading investments in medical device, diagnostic, and therapeutic companies, and serving in various board and advisory roles at numerous companies. He was Vice President of Commercialization Life Sciences for Battelle Memorial Institute, leading start-up formation, development of strategic partnerships, and internal corporate consulting teams. Prior to that he served as CEO of Progenics Inc. and was a member of the founding management team at Neoprobe Corporation, holding positions of CFO, VP of Manufacturing and VP of Product and Market Planning.

Mr. Kleinhenz has been active in technology-based economic development issues in Ohio and across the Mid-West. He earned an M.B.A. from Case Western Reserve University and a bachelor's degree from Loyola University of Chicago.